Hyperfine, Inc.
HYPR Nasdaq Electromedical & Electrotherapeutic Apparatus Financials FY2020โFY2025
Last close ยท Oct 23, 2026
$0.72
0.2%What Hyperfine, Inc. does
No business description yet.
- Legal name
- Hyperfine, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Mar 18, 2026
- Accession ยท CIK
- 0001193125-26-114044
0001833769
Revenue and margins
Hyperfine, Inc. had $13.6M of revenue in fiscal 2025, up 5.2% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was โ$29.1M in fiscal 2025, โ214.8% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Hyperfine, Inc. returned โ to shareholders in fiscal 2025. The diluted share count rose 13.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably Hyperfine, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $188M | $117M | $75.2M | $37.6M | $35.1M |
| Debt incl. finance leases | โ | โ | โ | โ | $0.0M |
| Debt / equity | โ | โ | โ | โ | 0.0x |
| Current ratio | 12.5x | 14.6x | 10.1x | 6.2x | 4.3x |
| Quick ratio | 12.3x | 14.1x | 9.4x | 5.5x | 3.7x |
| Total assets | $202M | $134M | $94.2M | $58.9M | $55.3M |
| Total liabilities | $16.2M | $10.3M | $9.8M | $9.9M | $14.3M |
| Shareholders' equity | $186M | $124M | $84.4M | $49.0M | $41.0M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ$35.1M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | 4 / 8 | 3 / 8 | 3 / 8 | 3 / 8 | 4 / 8 |
| Accruals ratio | โ2.7% | โ12.9% | 16.7% | โ2.1% | โ2.6% | โ13.4% |
| Altman Z'' | โ14.50 | 13.58 | 9.64 | 2.41 | โ11.00 | โ16.31 |
6 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $0.3M | $1.5M | $6.8M | $11.0M | $12.9M | $13.6M |
| Gross profit | โ$0.5M | โ$1.2M | $0.9M | $4.8M | $5.9M | $6.8M |
| Research and development | $14.6M | $25.8M | $28.2M | $22.5M | $22.5M | $17.5M |
| Operating income | โ$23.5M | โ$64.9M | โ$73.9M | โ$48.1M | โ$43.2M | โ$37.1M |
| Pretax income | โ$23.4M | โ$64.9M | โ$73.2M | โ$44.2M | โ$40.7M | โ$35.6M |
| Income tax | โ | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | โ$23.4M | โ$64.9M | โ$44.2M | โ$44.2M | โ$40.7M | โ$35.6M |
| Net income to common | โ$23.4M | โ$64.9M | โ$73.2M | โ$44.2M | โ$40.7M | โ$35.6M |
| Diluted EPS | โ$15.38 | โ$17.57 | โ$1.04 | โ$0.62 | โ$0.56 | โ$0.43 |
| Diluted shares | 0.00B | 0.00B | 0.07B | 0.07B | 0.07B | 0.08B |
| Cash flow | ||||||
| Cash from operations | โ$21.5M | โ$47.2M | โ$72.3M | โ$41.8M | โ$38.8M | โ$27.9M |
| Capital expenditure | $1.6M | $2.7M | $0.6M | $0.8M | $0.4M | $1.2M |
| Free cash flow | โ$23.1M | โ$49.9M | โ$72.9M | โ$42.6M | โ$39.2M | โ$29.1M |
| Depreciation and amortization | $0.3M | $0.7M | $1.0M | $1.1M | $1.0M | $1.1M |
| Stock-based compensation | $1.1M | $6.9M | $10.7M | $4.7M | $4.4M | $2.8M |
| Balance sheet | ||||||
| Cash and short-term investments | $62.7M | $188M | $117M | $75.2M | $37.6M | $35.1M |
| Total debt | โ | โ | โ | โ | โ | $0.0M |
| Current assets | $68.3M | $197M | $129M | $88.9M | $53.7M | $50.9M |
| Current liabilities | $4.1M | $15.7M | $8.8M | $8.8M | $8.7M | $11.7M |
| Inventory | $1.7M | $4.3M | $4.6M | $6.6M | $5.8M | $7.1M |
| Property and equipment, net | $1.9M | $3.8M | $3.2M | $3.0M | $3.1M | $2.5M |
| Total assets | $71.5M | $202M | $134M | $94.2M | $58.9M | $55.3M |
| Total liabilities | $4.3M | $16.2M | $10.3M | $9.8M | $9.9M | $14.3M |
| Shareholders' equity | โ$61.1M | $186M | $124M | $84.4M | $49.0M | $41.0M |
| Margins | ||||||
| Gross margin | โ162.2% | โ78.0% | 13.3% | 43.1% | 45.7% | 49.8% |
| Operating margin | โ7,990.1% | โ4,336.1% | โ1,084.2% | โ436.1% | โ335.3% | โ273.4% |
| EBITDA margin | โ7,891.8% | โ4,287.6% | โ1,069.3% | โ426.6% | โ327.5% | โ265.4% |
| Net margin | โ7,968.4% | โ4,335.0% | โ649.2% | โ401.0% | โ315.9% | โ262.3% |
| FCF margin | โ7,854.8% | โ3,335.1% | โ1,070.2% | โ386.3% | โ303.7% | โ214.8% |
| Returns | ||||||
| Return on capital | โ | โ | โ | โ | โ | โ494.9% |
| Return on capital employed | โ34.8% | โ34.7% | โ59.0% | โ56.3% | โ86.2% | โ85.2% |
| Return on equity | โ | โ103.6% | โ28.5% | โ42.5% | โ61.0% | โ79.0% |
| Return on assets | โ32.8% | โ47.3% | โ26.3% | โ38.8% | โ53.2% | โ62.3% |
| Return on tangible equity | โ | โ34.8% | โ59.1% | โ52.4% | โ83.0% | โ86.8% |
| Growth | ||||||
| Revenue growth | โ | 408.8% | 355.5% | 61.9% | 16.8% | 5.2% |
| Share count change | โ | 142.3% | 1,808.9% | 1.2% | 1.5% | 13.0% |
| Financial health | ||||||
| Debt / equity | โ | โ | โ | โ | โ | 0.0x |
| Current ratio | 16.6x | 12.5x | 14.6x | 10.1x | 6.2x | 4.3x |
| Quick ratio | 16.2x | 12.3x | 14.1x | 9.4x | 5.5x | 3.7x |
| Capital allocation | ||||||
| Capex / revenue | 533.3% | 181.2% | 8.6% | 7.3% | 3.0% | 8.7% |
| Stock comp / revenue | 379.9% | 461.3% | 156.3% | 43.0% | 33.8% | 20.7% |
| Quality scores | ||||||
| Piotroski F-score | โ | 4.0 | 3.0 | 3.0 | 3.0 | 4.0 |
| Altman Z'' | โ14.5 | 13.6 | 9.6 | 2.4 | โ11.0 | โ16.3 |
| Accruals ratio | โ2.7% | โ12.9% | 16.7% | โ2.1% | โ2.6% | โ13.4% |
Source: SEC EDGAR XBRL filings (CIK 0001833769). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.
